Clinical trial · no report yet · Phase 3
PATAPSCO
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
- NCT05943106 ↗
- Active not recruiting
- AstraZeneca
- 10 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 6 | |
| Podcasts | 3 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination With Durvalumab in Adult BCG-naïve, High-risk Non-Muscle- Invasive Bladder Cancer Participants (PATAPSCO)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-Muscle- Invasive Bladder Cancer
- Interventions
- Durvalumab; BCG
- Arms
- Durvalumab + BCG · Experimental
- Enrollment
- 100
- Primary outcomes
- Incidence of Grade 3 or 4 Possibly related adverse events (PRAEs)
- Sponsor
- AstraZeneca with Parexel
- Start
- Aug 11, 2023
- Primary completion
- Jun 16, 2025
- Results posted
- No
- Registry record
- NCT05943106 · updated Aug 13, 2026